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SUMMARY 
Neuroinflammation is one of the most striking hallmarks of amyotrophic lateral sclerosis (ALS). Nuclear 
Factor-kappa B (NF-κB), a master regulator of inflammation, is upregulated in spinal cords of ALS patients and 
SOD1-G93A mice.  In this study, we show that selective NF-κB inhibition in ALS astrocytes is not sufficient to 
rescue motor neuron (MN) death. However, the localization of NF-κB activity and subsequent deletion of NF-
κB signaling in microglia led to rescued MNs from microglial-mediated death in vitro and extended survival in 
ALS mice by impairing pro-inflammatory microglial activation.  Conversely, constitutive activation of NF-κB 
selectively in WT microglia induced gliosis and MN death in vitro and in vivo. Taken together, these data 
provide a mechanism by which microglia induce MN death in ALS, and suggest a novel therapeutic target that 
can be modulated to slow the progression of ALS and possibly other neurodegenerative diseases by which 
microglial activation plays a role. 
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INTRODUCTION 
 Amyotrophic lateral sclerosis (ALS) is a devastating, fast-progressing neurodegenerative disease 
characterized by motor neuron (MN) death in the brainstem, spinal cord, and motor cortex.  Typically within 2-5 
years of clinical onset, patients succumb to the disease due to severe muscle atrophy, paralysis, and ultimately 
denervation of respiratory muscles.  Most ALS cases are classified as sporadic, defined as having no family 
history of the disease.  The remaining 5-10% of cases are classified as familial and are typically inherited in an 
autosomal dominant fashion.  Despite genetic differences, these two forms of ALS are clinically 
indistinguishable.  Approximately 20% of familial cases are associated with mutations in the gene superoxide 
dismutase 1 (SOD1) (Rosen et al., 1993).  Transgenic rodents carrying mutant forms of SOD1 develop a 
similar, progressive MN disease akin to patients and are used as the gold standard in ALS research.  Elegant 
studies using these animals have shown that non-neuronal cells play a crucial role in ALS, contributing to MN 
death via non-cell autonomous mechanisms (Clement et al., 2003).  Similarly, in vitro studies have shown that 
murine astrocytes and microglia expressing mutant SOD1 and human astrocytes from sporadic and familial 
ALS patients can induce MN death (Di Giorgio et al., 2008; 2007; Haidet-Phillips et al., 2011; Marchetto et al., 
2008; Nagai et al., 2007; Xiao et al., 2007). Evidence that individual cell types mediate different aspects of 
disease emerged from the generation of mice expressing a conditional deletion of the mutant SOD1 gene.   
Removal of mutant SOD1 specifically in MNs extended survival by delaying disease onset and early disease 
progression, while excising flox’ed mutant SOD1 in either microglia/macrophages or astrocytes extended 
survival by slowing disease progression, but not onset (Boillee et al., 2006; Yamanaka et al., 2008).  Similarly, 
replacing the myeloid lineage of mutant SOD1 mice with WT microglia/macrophages slowed disease 
progression (Beers et al., 2006).  This suggests ALS is a deadly convergence of damage developed in multiple 
cellular compartments that ultimately leads to neuromuscular failure.  However, the precise mechanisms by 
which individual cell types such as astrocytes and microglia contribute to the disease remain unknown.   
 One of the most striking hallmarks of ALS shared by familial and sporadic patients as well as rodent 
models is neuroinflammation, characterized by extensive astrogliosis, microglial activation, and infiltration of 
peripheral immune cells at sites of neurodegeneration (Alexianu et al., 2001; Hall et al., 1998; Kawamata et al., 
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1992; Mantovani et al., 2009; Turner et al., 2004).  Mutant SOD1 astrocytes and microglia exhibit increased 
expression of many pro-inflammatory genes (Philips and Robberecht, 2011).  However, genetic approaches to 
globally eliminate single inflammatory genes in ALS mouse models have largely failed to extend survival 
(Almer et al., 2006; Gowing et al., 2006; Nguyen et al., 2001; Son et al., 2001) and in some cases have even 
hastened disease progression (Lerman et al., 2012), highlighting the complexity of neuroinflammation in ALS.  
For these reasons a successful therapeutic approach is likely to derive from a better understanding of the 
intricate molecular mechanisms driving the inflammatory response and the identification of up-stream 
transcription factors that are dysregulated in each cellular compartment throughout the course of disease.   
 Classical NF-κB signaling involving the p65/p50 heterodimer is a major regulator of inflammation, 
driving gene expression of pro-inflammatory cytokines, chemokines, enzymes and adhesion molecules, many 
of which are upregulated in ALS.  When inflammatory mediators bind their respective receptors, a signaling 
cascade is initiated that leads to phosphorylation and activation of IKKβ (a subunit of the inhibitor of IκB 
kinase, IKK, complex).  Activated IKKβ phosphorylates the IκB inhibitory protein IκBα, targeting it for 
ubiquitination and proteasomal degradation, and subsequent release of NF-κB (p65/p50) to the nucleus where 
it binds to its cognate DNA sequences to induce gene expression (Ghosh and Karin, 2002). Additionally, 
phosphorylation at specific serine residues by IKKβ are required for transactivation function of the p65 subunit 
of NF-κB (Hayden and Ghosh, 2008).  We previously reported NF-κB as the highest-ranked regulator of 
inflammation by Ingenuity Pathway analysis of inflammatory gene array data from astrocytes derived from 
human post mortem ALS patients (Haidet-Phillips et al., 2011). Other laboratories have confirmed by 
immunohistochemistry that NF-κB is activated in glia in familial and sporadic ALS patients (Swarup et al., 
2011).  Interestingly, loss of function mutations in the gene optineurin, which is known to negatively regulate 
TNF-α-induced NF-κB activation, have been found in ALS patients (Maruyama et al., 2011).  However, it 
remains unknown whether NF-κB activation in ALS glia is involved in MN death. 
 Since the role of glial-derived inflammation in ALS remains ambiguous, we sought to determine 
whether inflammatory signaling regulated by NF-κB in astrocytes and microglia mediates MN death in ALS.  In 
the current study we demonstrate that NF-κB is activated with disease progression in the SOD1-G93A mouse 
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model, specifically in glia.  In agreement with recent publications, inhibition of NF-κB in astrocytes, using both 
transgenic and viral-mediated gene delivery approaches, did not increase motor function or survival in our 
SOD1-G93A mice (Crosio et al., 2011a).  However, inhibition of NF-κB selectively in microglia, rescues MN 
survival in vitro, and in vivo extends survival in the ALS mice by delaying disease progression by 47%, one of 
the longest extensions reported in this severe model.  NF-κB inhibition in microglia leads to marked reduction 
in prototypic inflammatory markers, suggesting that NF-κB regulates microglial conversion to a pro-
inflammatory, neurotoxic state in ALS.  Conversely, we show that constitutive activation of NF-κB selectively in 
myeloid cells in WT mice creates the pathological features of ALS in the spinal cord, i.e., gliosis and MN death.  
Together, these data indicate that NF-κB activation in microglia is a novel molecular mechanism underlying 
MN death in ALS. Moreover, the data identify a new therapeutic target to modulate microglial activation and 
slow the progression of ALS and other neurodegenerative diseases in which microglial activation plays a role.    
RESULTS 
NF-κB is activated with disease progression in the SOD1-G93A mouse model of ALS 
 In order to gain insight into NF-κB regulation in ALS, we performed electrophoretic mobility shift assay 
(EMSA) analysis on whole spinal cord nuclear lysates from the SOD1-G93A mouse model.  NF-κB DNA 
binding activity was increased in end-stage ALS mice compared to WT littermates (Figure S1A).  Supershift 
EMSA analysis revealed the binding contribution of p65 (Figure S1B).  Interestingly, we were unable to show a 
supershift using antisera against p50, c-Rel, and RelB subunits, which may be more of a limitation of the 
antibody than the lack of presence of these NF-κB subunits in spinal cords of SOD1-G93A mice.  To 
investigate the extent of p65-mediated classical NF-κB activation in the SOD1-G93A mouse model at different 
stages of disease, whole lumbar spinal cord protein was analyzed for the transcriptionally active, 
phosphorylated form of p65 from three SOD1-G93A female mice at the pre-symptomatic stage (pre-sym), 
disease onset, symptomatic (sym), late-symptomatic (late-sym), and end-stage (ES).  We found that as 
diseased progressed in ALS animals, phospho-p65 levels increased modestly from pre-sym to sym, although 
fold changes were not statistically significant.  However, at late-SYM phospho-p65 levels were 13.7-fold 
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greater in SOD1-G93A mice compared to WT and 8.7-fold greater than WT at ES (Figure 1A and 1B). In order 
to determine whether the increase in phospho-p65 levels observed at late-sym stages is statistically different 
compared to the levels at ES, we analyzed lumbar spinal cord lysates from additional late-sym (n=6) and ES 
SOD1-G93A mice (n=6), revealing no statistical difference in NF-κB activation between late-sym and ES 
(Figure S1C and S1D).  To determine the contribution of astrocytes to this increase, we isolated primary 
astrocytes from the spinal cords of WT and SOD1-G93A mice at the late-sym stage. Western blot analysis 
showed a 4.4-fold increase in phospho-p65 in ALS astrocytes compared to WT (Figure 1C). 	  
NF-κB inhibition in astrocytes does not confer neuroprotection in vitro or in vivo in the SOD1-G93A 
mice 
To determine the relevance of NF-κB activation to astrocyte-mediated MN death in ALS, we tested NF-
κB inhibition in an in vitro co-culture model of familial ALS.  We utilized an embryonic stem cell line containing 
an Hb9-GFP reporter, which we and others have shown recapitulate aspects of MN pathology and cell death 
when co-cultured with ALS glia (Di Giorgio et al., 2007; Haidet-Phillips et al., 2011; Nagai et al., 2007; 
Wichterle et al., 2002).  After 5 days in co-culture, the number of MNs present on SOD1-G93A astrocytes was 
statistically reduced by 49% compared to the MNs surviving on WT astrocytes (Figure S2A).  To test the role of 
NF-κB in SOD1-G93A astrocytes, we utilized an adenovirus expressing the transdominant super repressor 
inhibitor of NF-κB (IκBα-SR).  IκBα-SR is an IκBα mutant that is resistant to phosphorylation-induced 
degradation thus blocking phosphorylation sites of p65 and inhibiting transcriptional function of the NF-κB 
complex (Wang et al., 1999).  We confirmed that adenoviral vectors were capable of targeting nearly 100% of 
astrocytes in vitro (data not shown) (Miranda et al., 2012).  However, overexpression of IκBα-SR in SOD1-
G93A astrocytes did not rescue MN death in vitro despite being functional and decreasing phospho-p65 levels 
(Figure S2A and S2B).  In fact, there were less MNs surviving after 4 days in co-culture with SOD1-G93A 
astrocytes overexpressing IκBα-SR compared to SOD1-G93A astrocytes, however, significance was lost on 
subsequent days (Figure S2A). 
Since our in vitro model may not fully recapitulate all aspects of astrocyte-induced pathology in ALS, we 
simultaneously tested NF-κB inhibition in vivo using two independent, cell type-specific approaches: viral-
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mediated gene delivery and transgenic cre-lox recombination.  As a therapeutically relevant study, we injected 
SOD1-G93A mice with adeno-associated viral vector serotype 9 (AAV9) to deliver IκBα-SR.  Mice were 
injected at postnatal day 60 to preferentially target >50% astrocytes in the CNS (Foust et al., 2008; 2013).  
Consistent with the in vitro data above, overexpression of IκBα-SR in astrocytes utilizing AAV9 did not alter 
survival nor improve motor performance in the SOD1-G93A mice compared to non-injected controls (Figure 1D 
and E) or SOD1-G93A mice injected with AAV9-GFP (Foust 2013).   
To transgenically inhibit NF-κB in astrocytes in SOD1-G93A mice, we mated SOD1-G93A mice to mice 
with conditional mutants of IKKβ (IKKβf/f), which have exon 3 of the ikbkb (IKKβ) gene flanked by loxP sites (Li 
et al., 2003; Park et al., 2002).  We crossed these mice to a strain expressing cre recombinase under the 
regulation of the glial fibrillary acidic protein (GFAP) promoter, thus ablating IKKβ and downstream NF-κB 
activity specifically in astrocytes.  We confirmed cre expression was restricted to GFAP-expressing astrocytes 
in the spinal cord by crossing GFAP-cre mice to a Rosa26 line that expresses tdTomato (RFP) in all cre-
expressing cells (Figure S2C).  We observed robust RFP expression in GFAP+ and EAAT2+ cells (Figure 
S2D); RFP expression was absent in Iba-1+ microglia as well as in ChAT+ neurons in the spinal cord as 
previously reported (Figure S2C) (Yamanaka et al., 2008; Zhuo et al., 2001).   Immunoblot of lumbar spinal 
cord protein demonstrated a 58% reduction in phospho-p65 levels in SOD1; IKKβf/f; GFAP-cre+ mice 
compared to SOD1 cre- mice at the symptomatic stage of disease (Figure S2E).  Despite the reduction in 
phospho-p65, motor impairment and survival in the GFAP-cre+ mice were not improved compared to GFAP-
cre- negative controls (Figure 1F and 1G).  Indeed, our findings are consistent with a recent study crossing 
ALS mice to a strain overexpressing IκBα-SR under the GFAP promoter (Crosio et al., 2011b). 
NF-κB activation occurs predominately in microglia in the SOD1-G93A mouse model 
To evaluate whether astrocytes are the main cells contributing to the increase in lumbar NF-κB 
activation, we crossed the SOD1-G93A mice to a NF-κB-GFP reporter mouse strain that expresses GFP under 
the control of NF-κB cis elements (Magness et al., 2004).  Since robust NF-κB activation in SOD1-G93A was 
evident at late stages of disease in lumbar spinal cord protein, we analyzed lumbar spinal cord sections from 
late-sym SOD1; NF-κB-GFP mice for GFP expression.  We observed a population of bright GFP+ cells 
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identified as microglia by overlapping confocal Iba-1 staining (Figure 2A).   We also observed a dim GFP+ 
population of GFAP+ astrocytes (Figure 2B).  We confirmed these findings by analyzing phospho-p65 levels in 
protein from microglia isolated from late-sym SOD1-G93A mice.   Impressively, phospho-p65 was 12.4 fold 
greater in SOD1-G93A microglia than WT microglia (Figure 2C).  To determine the time course of NF-κB 
activation in microglia as disease progressed, we performed immunohistochemistry of SOD1; NF-κB-GFP 
lumbar spinal cord sections at pre-sym, onset, sym, late-sym, and at ES.  We observed that majority of bright 
and dim GFP+ cells co-localized with the microglial marker tomato lectin at disease onset with an increase in 
the number and GFP intensity as disease progressed, coinciding with microglial activation and gliosis (Figure 
2D and 2E).  These data reveal that microglia contribute to the robust NF-κB activation that occurs during ALS 
disease progression.  
Adult SOD1-G93A microglia are toxic to MNs in vitro   
To study the mechanisms by which microglia mediate MN death in ALS and the contribution of NF-κB 
activation to this process, we sought to establish an in vitro co-culture model of ALS.  We found no difference 
in MN survival when MNs were co-cultured with SOD1-G93A primary neonatal microglia compared to WT 
(Figure S3), suggesting these young cells were not recapitulating important aspects of the adult-onset 
neurodegenerative disease.  Therefore, we established a co-culture utilizing primary adult microglia isolated 
from symptomatic ALS mice.  We utilized a previously described method that combines density separation and 
culture selection (Moussaud and Draheim, 2010).  Immunocytochemical characterization of adult microglia 
obtained by this method were positive for prototypic microglial markers including Iba-1, CD11b, and F4/80 and 
negative for GFAP, ChAT, and NG2 (Figure 3A and B).  Flow cytometry confirmed that this technique yields a 
homogenous population of microglia (Figure 3C). We observed no difference in our assays when we used 
spinal cord or brain-derived microglia, therefore, to decrease the number of animals used, we performed 
experiments using brain microglia.  
To determine the capacity for SOD1-G93A adult microglia to induce MN death, we co-cultured WT 
Hb9:GFP+ MNs with WT or SOD1-G93A microglia.  After 72 hours, MN numbers decreased 50% when co-
cultured with SOD1-G93A microglia compared to WT microglia (Figure 3D and 3E).  To confirm that MN death 
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is specific to the causative SOD1 mutation, we overexpressed a shRNA targeting the human SOD1 transgene 
in the SOD1-G93A microglia by lentivirus, shown to reduce mutant protein by 75% (Figure 3F).  When mutant 
SOD1 protein was reduced in SOD1-G93A microglia, MNs survival was rescued (Figure 3D and 3E).  
Adult SOD1-G93A microglia induce MN death in an NF-κB dependent mechanism in vitro.   
 To examine whether NF-κB activation in microglia is involved in MN death in vitro, we employed two 
independent approaches to abolish NF-κB activation in microglia. First, we overexpressed IκBα-SR via 
adenovirus (Ad-IκBα-SR) in SOD1-G93A and WT microglia.  We also employed a genetic approach by 
isolating microglia from SOD1-G93A; IKKβf/f mice and infecting the microglia in vitro with an adenovirus 
expressing cre recombinase (Ad-cre) to remove IKKβf/f in microglia post-isolation.  After 12 hours, we observed 
no difference in survival or axon length of the MNs co-cultured with SOD1-G93A or WT microglia (Figure 4A).  
However, after 72 hours of co-culture there was a 61% reduction in MN survival and marked reduction in axon 
length when MNs were co-cultured with SOD1-G93A microglia compared to WT (Figure 4B).  Live-imaging of 
these co-cultures captures the dynamic nature of microglia and rapid MN death induced by SOD1-G93A 
microglia (Movie S1 and S2).   Initially, WT microglia phagocytosed MN debris generated from the FACS 
sorting and plating.  Then WT microglia proceeded to actively survey synapses of MNs, not disrupting intact 
synapses.  On the contrary, SOD1-G93A microglia assaulted intact synapses, thus causing axonal damage 
and MN death, finishing with phagocytosis of the neuronal debris.  Remarkably, NF-κB inhibition, either 
transgenically or by overexpression of IκBα-SR, fully rescued MN axon length and survival in vitro to WT levels 
(Figure 4A and 4B).  Live-imaging shows SOD1-G93A microglia with NF-κB inhibition preserved intact MNs 
similar to WT microglia (Movie S3 and Movie S4).  We evaluated the efficiency of NF-κB induction by 
measuring nitric oxide (NO) and TNF-α levels in the co-culture medium, both of which are products of classical 
NF-κB activation and inflammatory microglia (Ghosh and Karin, 2002).  TNF-α levels decreased by 45% and 
by 64% when NF-κB was inhibited in SOD1-G93A microglia using Ad-IκBα-SR and Ad-cre, respectively 
(Figure 4C).  Nitric oxide (NO) levels were reduced by 71% and by 56% in SOD1-G93A microglia using Ad-
IκBα-SR and Ad-cre, respectively (Figure 4D).  Corresponding with TNF-α and NO levels, phospho-p65 was 
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reduced by 79% and 81% using Ad-IκBα-SR and Ad-cre, respectively, compared to SOD1-G93A microglia 
(Figure 4E).  To confirm NF-κB transcriptional activity was reduced with Ad-IκBα-SR and Ad-cre, we performed 
an NF-κB luciferase assay.  Firefly luciferase activity normalized to renilla luciferase was 6.2-fold greater in 
SOD1-G93A microglia compared to wild-type and Ad-IκBα-SR and Ad-cre both reduced NF-κB-dependent 
luciferase activity in SOD1-G93A microglia to near wild-type levels (Figure 4F).  These data suggest that 
SOD1-G93A microglia induce MN death in an NF-κB-dependent mechanism. 
SOD1-G93A microglia induce MN death in an NF-κB dependent mechanism in vivo. 
    Since we have established that (1) NF-κB activation during the disease course in SOD1-G93A mice 
occurs in microglia (Figure 2) and (2) SOD1-G93A microglia kill MNs in vitro via an NF-κB-dependent 
mechanism (Figure 4), we tested the hypothesis that NF-κB inhibition in microglia would attenuate disease in 
SOD1-G93A mice.  To do so, we crossed SOD1-G93A; IKKβf/f mice to mice expressing cre recombinase 
driven by the promoter for the gene c-fms which encodes Colony Stimulating Factor Receptor 1 (CSF-1R).  As 
shown by MacGreen reporter mice that express GFP under the regulation of the c-fms promoter, CSF-1R is 
expressed throughout the mononuclear phagocyte system of the mouse, but only microglia express CSF-1R in 
the postnatal mouse brain (Erblich et al., 2011; Sasmono and Williams, 2012; Sasmono et al., 2003).  To 
confirm cell-type specificity of cre expression driven by the c-fms (CSF-1R) promoter, we crossed CSF-1R-cre 
mice to the Rosa26-Td-Tomato mouse strain.  We observed RFP expression only in Iba-1-positive microglia in 
the adult mouse spinal cord, and RFP expression was absent in MNs and astrocytes (Figure S4A and S4B). 
 Mice homozygous for IKKβ (IKKβf/f), both SOD1 and WT, displayed serious immune dysfunction such 
as enlarged spleens, eye infections, and missing or very brittle teeth which have been previously reported in 
mice with myeloid cells devoid of NF-κB (Ruocco et al., 2005; Vallabhapurapu and Karin, 2013). These mice 
could not be maintained in the colony long enough to evaluate survival, thus, we analyzed IKKβf/wt 
heterozygous mice.  To determine the efficiency of IKKβ knockdown in these heterozygotes, 
immunohistochemistry was performed probing for IKKβ in lumbar spinal cord sections from SOD1-G93A; 
IKKβf/wt; CSF-1R-cre+ and cre- mice.   SOD1-G93A; IKKβf/wt; CSF-1R-cre+ showed a decrease in IKKβ 
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staining compared to cre negative controls (Figure S4C).  To ensure knockdown was specific for IKKβ, we 
evaluated IKKγ, the regulatory subunit of the IKK signaling complex, and observed no difference between 
CSF-1R-cre+ and cre- mice (Figure S4C).  Remarkably, reducing IKKβ, and thus NF-κB activation, resulted in 
a pronounced 20 day extension in median survival in SOD1-G93A; IKKβf/wt; CSF-1R-cre+ mice compared to 
cre- controls (133 days in cre- and 153 days in cre+)  (Figure 5A).  While disease onset was not altered 
(102.8±1.1 days in cre- and 101.1±1.3 days in cre+), disease progression was significantly extended by 47% in 
cre+ mice compared to cre- mice (34.8±1.4 days in cre- and 51.1.1±1.7 days in cre+) (Figure 5B and 5C).  
Video of age-matched littermates show SOD1-G93A; IKKβf/wt; CSF-1R-cre+ mouse able to ambulate around 
cage while SOD1-G93A; IKKβf/wt; CSF-1R-cre- littermate is at ES (Movie S5). To confirm the level of NF-κB 
inhibition that was achieved to slow disease progression by 47%, we analyzed lumbar spinal cord protein for 
phospho-p65 from SOD1-G93A; IKKβf/wt; CSF-1R-cre+ or cre- mice at ES.  Remarkably, phospho-p65 was 
reduced by 44% in SOD1-G93A; IKKβf/wt; CSF-1R-cre+ mice compared to cre- SOD1 controls, which 
expressed 7.5 fold more phospho-p65 than WT controls.  This is consistent with the 40% decrease in IKKβ we 
observed in SOD1-G93A; IKKβf/wt; CSF-1R-cre+ mice compared to cre- controls (Figure 5D). Notably, NF-κB 
inhibition did not reduce the levels of mutant SOD1 in CSF-1R-cre+ mice compared to cre- SOD1 control mice 
(Figure 5D). 
 To determine the impact of NF-κB inhibition on astrogliosis and microgliosis, we analyzed lumbar spinal 
cord sections by immunohistochemistry for intensity of GFAP and Iba-1, respectively.  No difference in gliosis 
could be detected between ES SOD1-G93A; IKKβf/wt; CSF-1R-cre+ and cre- mice (data not shown).  However, 
considering that SOD1-G93A; IKKβf/wt; CSF-1R-cre+ endured disease for an additional 3 weeks compared to 
controls, it is possible that differences in gliosis achieved earlier in disease are lost at ES.  Indeed, when we 
sacrificed the SOD1-G93A; IKKβf/wt; CSF-1R-cre+ mice at the same age as the cre- littermate control reached 
end-point, we observed a significant decrease in signal intensity of GFAP by 31% and of Iba-1 by 25%, 
indicating astrogliosis and microgliosis are decreased in CSF-1R-cre+ mice compared to age-matched controls 
(Figure 5E-5G).  
NF-κB regulates SOD1-G93A microglial conversion to an inflammatory, neurotoxic phenotype 
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 We hypothesized that the increased survival observed in SOD1-G93A; IKKβf/wt; CSF-1R-cre+ mice was 
due to a dampened inflammatory microglial response. To characterize microglia phenotype, antibodies specific 
for CD68, iNOS, and CD86 were used to label microglia exhibiting an M1 inflammatory phenotype (Kigerl et al., 
2009).   As disease progresses, we and others have observed SOD1-G93A mice exhibit a robust induction in 
CD68-positive microglia that is greatest at ES (data not shown) (Beers et al., 2011b; Chiu et al., 2013).  We 
found a marked reduction in the number of CD68 positive microglia in SOD1-G93A; IKKβf/wt; CSF-1R-cre+ 
mice (112.4 ± 4.7 cells/section) compared to cre-negative controls (438.3 ± 13.4 cells/section) (Figure 6A and 
6B).  The number of iNOS+/Iba1+ cells/section was also significantly reduced from 251.1 ± 15.0 in controls to 
47.8 ± 3.1 in mice with microglial NF-κB inhibition (Figure 6C, 6D).  Following the same trend, mice with 
microglial NF-κB inhibition showed substantial reduction of CD86+/Iba1+ cells (97.8 ± 7.4 per section) 
compared to SOD1 controls (320.3 ± 15.6 cells per section) (Figure 6E and 6F).  We did not observe any 
alterations in the M2 markers CD206, arginase, CD204 by immunohistochemistry, suggesting that while we 
inhibited M1 microglia, NF-κB inhibition did not promote an M2 phenotype (data not shown).   
NF-κB activation selectively in WT microglia is sufficient to induce MN death in vitro 
We hypothesized that if NF-κB activation is the mechanism by which SOD1-G93A microglia induce MN 
death, constitutively activating NF-κB in WT microglia should be sufficient to induce MN death.  To test this 
hypothesis we isolated microglia from Rosa26-StopFloxIKKβCA mice containing inducible constitutively active 
IKKβ (IKKβ CA).  Post-isolation we infected microglia from these mice with an adenovirus expressing cre 
recombinase (Ad-cre) to induce transcription of constitutively active IKKβ (microglia termed IKKβCA) or Ad-
RFP as control (microglia termed WT).  After 12 hours in co-culture with WT or IKKβCA microglia, we observed 
no difference in MN axon length or survival (Figure 7A).  Interestingly, after 72 hours in co-culture IKKβCA 
microglia induced a 50% statistical decrease in MN survival compared to controls (Figure 7A, 7B).  Live-
imaging shows IKKβCA microglia rapidly inducing MN death (Movie S6).  We confirmed NF-κB activation by 
ELISA, showing 1.7-fold greater phospho-p65/total p65 in IKKβCA microglia compared to WT (Figure 7C).  
Similarly, NF-κB-dependent luciferase activity normalized to renilla was 1.5-fold greater in IKKβCA microglia 
compared to WT (Figure S5A).  Additionally, TNF-α levels increased 2.3-fold in co-cultures with IKKβCA 
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microglia compared to WT, which is comparable to TNF-α induction by SOD1-G93A microglia and 
characteristic of activated microglia (Figure S5B).  Similarly, nitric oxide (NO) levels in IKKβCA microglia/MN 
co-culture were 1.5 fold greater than WT (Figure S5C).  These data suggest that constitutive NF-κB activation 
in microglia is sufficient to induce MN death independent of SOD1 mutations.   
NF-κB regulates microglial activation to an inflammatory, neurotoxic phenotype 
Since we observed a reduction in inflammatory microglial markers CD68, iNOS, and CD86 with NF-κB 
inhibition, we hypothesized that NF-κB is required for microglial activation.  Thus, we reasoned that selectively 
expressing constitutively active IKKβ (IKKβCA) in myeloid cells in vivo should induce an inflammatory state in 
WT microglia similar to that observed in ALS mice.  To test this notion, we crossed mice expressing CSF-1R-
cre to Rosa26-StopFloxIKKβCA mice (termed IKKβCA). IKKβCA mice exhibited an 8.2 fold increase in phospho-
p65 in lumbar spinal cord protein compared to cre-negative littermates, similar to levels in SOD1-G93A mice 
(Figure 7D).  Enhanced microglial activation at 4 and 8 months in these mice also was associated with 
pronounced astrocytosis (Figure 7E).   By 8 months we observed a striking 40% decrease in ChAT+ MNs in 
the lumbar spinal cord (Figure 7F) which coincided with decreased mass and hind-limb grip strength in IKKβCA 
mice compared to WT littermates (Figure 7G and 7H).  Thus, chronic activation of NF-κB signaling in myeloid 
cells creates the pathological features of ALS in the spinal cord, i.e., gliosis and MN death. While we focused 
on lumbar spinal MNs, it is likely other neurons and brain regions are affected by microglial activation in 
IKKβCA mice. 
To determine whether microglia in IKKβCA mice express activation markers, similar to those described 
above for activated (M1) microglia from SOD1-G93A mice, we analyzed microglia from the IKKβCA and cre-
negative littermates for expression of CD68, iNOS, and CD86.  A striking upregulation of CD68 and CD86 was 
observed in microglia from 4 month and 8 month-old IKKβCA mice (Figure S6A and S6B).  Microglia from 
IKKβCA mice also differed drastically from those found in WT controls exhibiting a de-ramified morphology with 
shorter, thickened processes shown by Iba-1 staining.  We detected an increase in iNOS+ microglia compared 
to WT controls at 8 months, but not at 4 months in IKKβCA mice (Figure S6C).  Interestingly, we observed an 
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increase in CD68 and CD86-positive microglia in 8 month WT controls compared to 4 month-old controls, 
which supports previous reports that microglial activation increases with aging (Norden and Godbout, 2013).  
These data suggest that chronic NF-κB activation induces an inflammatory (M1) microglia phenotype that 
causes MN death. 
DISCUSSION  
Landmark studies have shown selective removal of the causal mutant SOD1 gene from myeloid cells in 
the slow-progressing SOD1-G37R mice (Boillee et al., 2006) or repopulating the fast-progressing SOD1-G93A 
model with WT myeloid cells, delays disease progression (Beers et al., 2006).  Therefore, we hypothesized 
that if NF-κB activation is a mechanism by which mutant SOD1 microglia mediates MN death in ALS, then 
disease progression will be substantially delayed in SOD1-G93A mice with microglial NF-κB inhibition.  Mice 
homozygous for IKKβ (IKKβf/f), both SOD1 and WT, displayed serious immune dysfunction and could not be 
assessed for survival, so we generated SOD1; CSF1R-cre; IKKβF/+ heterozygous mice.  Strikingly, 
heterozygous inhibition of NF-κB specifically in the myeloid lineage of the fast-progressing SOD1-G93A mouse 
model significantly delayed disease progression by 47% resulting in a 20 day increase in survival.  Therefore, 
our data extend those showing that ALS microglia contribute to MN death in a non-cell autonomous 
mechanism, and for the first time we report that microglial-mediated MN death in ALS occurs through an NF-
κB-dependent mechanism. 
To determine the extent by which NF-κB inhibition in microglia alters the neuroinflammatory hallmarks 
of ALS pathology, we analyzed lumbar sections for astrogliosis, microgliosis and MN death.  In SOD1-G93A; 
IKKβf/wt; CSF1R-cre+ mice with NF-κB inhibition in microglia, we observed a decrease in Iba-1 and GFAP 
compared to age-matched cre-negative control littermates, suggesting NF-κB inhibition delayed microglial 
activation and astrogliosis during disease progression.  Additionally, we show NF-κB inhibition in astrocytes 
results in no benefit to ALS mice and in fact might be detrimental, which has been previously reported (Crosio 
et al., 2011b).  It is likely NF-κB might regulate important aspects of astrocyte function that are needed to 
support MNs under insult in ALS, which may explain why no benefit was observed with astroglial NF-κB 
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inhibition in SOD1-G93A mice (Beattie et al., 2002; Bracchi-Ricard et al., 2008).  These data suggest that 
astrocytes elicit a different non-cell autonomous mechanism than microglia to induce MN death in ALS.  
To determine whether the survival increase observed in SOD1-G93A; IKKβf/wt; CSF-1R-cre+ mice was 
due to a dampened pro-inflammatory microglial response, we characterized microglia for known markers of 
microglial activation. Depending on the milieu in which they become activated, microglia differentiate into 
inflammatory (M1) and anti-inflammatory (M2) effector cells with the potential to kill invading pathogens or 
neurons (M1), promote tissue repair or dampen the immune response (M2) (Kigerl et al., 2009). These 
activation states were characterized initially in macrophages in vitro and likely represent an oversimplification 
of the in vivo functional potential of these cell types (Mosser and Edwards, 2008; Ransohoff and Perry, 2009).  
Not surprisingly, ALS microglia have a unique pro-inflammatory (M1) gene signature compared to LPS-
stimulated M1 microglia (Chiu et al., 2013).  Previous reports showed an upregulation of genes in SOD1-G93A 
mice known to be expressed by inflammatory (or M1) microglia such as CD68, CD86, iNOS, TNF-α, NOX2, 
COX2, IL-6, and IL-1β, which increase with disease progression.  In fact, SOD1-G93A; IKKβf/wt; CSF-1R-cre+ 
mice exhibited a marked reduction in prototypic ALS microglia inflammatory markers such as CD68, CD86 and 
iNOS compared to cre-negative controls, suggesting pro-inflammatory, M1 microglia play a central role in MN 
death in ALS (Beers et al., 2011a; Henkel et al., 2009; Zhao et al., 2004).  Additionally, a recent report 
suggests infiltrating inflammatory monocytes contribute to MN death in ALS (Butovsky et al., 2012). Since 
CSF1R-cre is expressed in microglia and peripheral myeloid cells, we cannot exclude the possibility that the 
delay in disease progression we observe is due to NF-κB inhibition in peripheral macrophages or infiltrating 
monocytes.  To further address the contribution of peripheral myeloid cells to ALS, new cre mouse strains or 
viral vectors need to be developed that exclusively target microglia or peripheral macrophages/monocytes.   
Since NF-κB activation is the mechanism by which SOD1-G93A microglia induce MN death, we 
hypothesized that constitutively activating NF-κB in WT microglia should be sufficient to induce MN death.  
Interestingly, microglia with constitutively active NF-κB rapidly induced a 50% decrease in MN survival in vitro 
compared to controls through a mechanism that is independent of mutant SOD1.  Notably, 8 month old 
IKKβCA mice exhibit a marked reduction in spinal MNs, accompanied by reduced weight and grip strength, 
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indicative of muscle atrophy. While we cannot determine whether microglia or peripheral myeloid cells are 
inducing MN death, these data have strong implications for patients with familial mutations other than SOD1 
and sporadic ALS patients.  Recently, immunohistochemical studies showed that NF-κB is highly induced in 
microglia of sporadic patients and those with mutation in the gene Optinuerin, a negative regulator of TNF-
α, induced NF-κB activation that has been shown to cause ALS (Sako et al., 2012).  Additionally, TDP-43 and 
FUS have been shown to be co-activators of NF-κB, and NF-κB inhibition in transgenic mice overexpressing 
mutant TDP-43 ameliorated the disease phenotype (Swarup et al., 2011; Uranishi et al., 2001).  Furthermore, 
dysregulation of the NF-κB pathway in lymphoblastoid cell lines was identified by MetaCore analysis  in both 
C9ORF72 patients and non-C9ORF72 patients (Ismail et al., 2013).  Therefore, aberrant NF-κB activation 
could be driving the microglial inflammatory response in both familial and sporadic ALS and could be a 
universal therapeutic target for ALS.   
However, targeting NF-κB is complicated due to its diverse functions in different cell types in the CNS 
and periphery.  For example, NF-κB activation in glutamatergic neurons is involved in learning and memory, 
dendritic arborization, and axonal outgrowth (Gutierrez, 2005; Kaltschmidt et al., 2006). In the context of 
neurodegeneration, mice with selective inhibition of IKKβ in neuronal cells utilizing a CamkII cre-driver 
experienced more severe EAE symptoms and succumb to disease earlier due to their inability to induce 
neuronal expression of NF-κB-dependent neuroprotective and anti-apoptotic genes (Emmanouil et al., 2009; 
Taoufik et al., 2011).  Therefore, when targeting NF-κB in the CNS, cell-type specificity is likely required so that 
functional benefits achieved by dampening microglial inflammation are not masked by neuronal deficits 
induced by off-target neuronal NF-κB inhibition (Kaltschmidt and Kaltschmidt, 2009; Mattson and Meffert, 
2006).  
 The data presented here clearly demonstrate that NF-κB is a promising therapeutic target for ALS.  
Heterozygous inhibition of NF-κB in microglia substantially delayed disease progression in the severe SOD1-
G93A model.  Strikingly, NF-κB activation in WT microglia causes MN death in vitro as well as in vivo, 
independent of mutant SOD1.  This suggests traumatic events, environmental risks or pre-disposing genetic 
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factors that lead to chronic activation of NF-κB in microglia could trigger the pathogenic mechanism leading to 
MN death.  The present data provide important insight on how microglia induce MN degeneration in a familial 
model of ALS, but even more interestingly, provide a therapeutic target for both familial and sporadic ALS 
patients.   
EXPERIMENTAL PROCEDURES 
Transgenic mice 
All procedures were performed in accordance with the NIH Guidelines on the care and use of 
vertebrate animals and approved by the Institutional Animal Care and Use Committee of the Research Institute 
at Nationwide Children’s Hospital. Animals were housed under light:dark (12:12 h) cycle and provided with 
food and water ad libitum.  Transgenic female B6SJ/L(SOD1-G93A)1Gur/J mice and non-transgenic 
littermates (Jackson Laboratories) were utilized for time course immunoblot studies and primary cell isolations.  
Transgenic male B6SJ/L(SOD1-G93A)1Gur/J mice were used for breeding with other transgenic lines.  SOD1 
transgene copy number was confirmed by real time PCR.  SOD1-G93A-NFκBEGFP reporter mice were 
generated by breeding SOD1-G93A mice to C57BL/6 NFκBEGFP mice (Christian Jobin) (Magness et al., 2004).  
SOD1-G93A; hGFAP-cre; IKKβflox/flox were generated by breeding SOD1-G93A mice to FVB hGFAP-cre 
(Jackson Labs) mice that had been crossed to C57BL/6 IKKβflox/flox mice (Li et al., 2003). SOD1-G93A; CSF-
1R-icre; IKKβflox/wt were generated by breeding SOD1-G93A mice to C57BL/6 CSF-1R-cre mice (Deng et al., 
2010) that had been bred to IKKβflox/flox mice.  CSF1R-cre; IKKβCA were generated my breeding CSF-1R cre 
mice to C57BL/6 Rosa26-StopFloxIKKβCA mice (Jackson Labs).  Cre specificity was confirmed by crossing cre 
lines to C57BL/6 Rosa26-StopFlox-CAG-tdTomato (Jackson Labs) mice and assessed for tdTomato expression 
by immunohistochemistry.  Genotypes were determined by qualitative PCR using the primers in 
Supplementary Table 1. 
Microglia/MN co-culture 
Hb9-GFP+ MNs were plated in 96-well plates coated with laminin (5 µg/ml, Invitrogen) at a density of 
6,000 cells per well.  The day after microglia were plated on top of MNs at a density of 35,000 cells per well in 
MN media (DMEM:F12 (Invitrogen), 5% horse serum, 2% N2 (Invitrogen), 2% B27 (Invitrogen) + GDNF (10 
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ng/ml, Invitrogen), BDNF (10 ng/ml, Invitrogen), CNTF (10 ng/ml, Invitrogen).  The co-culture plate was imaged 
each day by the IN Cell Analyzer 6000 (GE Healthcare).   Images were processed and analyzed using IN Cell 
Developer Toolbox 1.9 and IN Cell Analyzer Workstation 3.7 software (GE Healthcare) to quantify number of 
surviving GFP+ MNs per well.   
Western blot  
Cells and tissues were homogenized in Tissue Protein Extraction Reagent (Pierce) with EDTA, 
Complete protease inhibitor (Roche) and Phospho-STOP (Roche). The samples were run on NuPAGE Novex 
4-12% Bis-Tris polyacrilamide gels and transferred to a PVDF membrane (Life Technologies). Blots were 
blocked in 5% milk powder, 0.5% BSA in PBS-Tween for 1h, and then incubated for overnight at 4°C with 
primary antibody.  Bound primary antibody was detected by horseradish peroxidase conjugated secondary 
antibody followed by chemiluminescence detection (ECL Western Blot Substrate, Pierce).  Antibodies are 
listed in Supplementary Table 2. 
Immunohistochemistry 
Animals were deeply anesthetized with a lethal dose of Xylazene/Ketamine and perfused transcardially 
with saline, then 4% paraformaldehyde.  Spinal cords were sectioned 40 µm thick using a vibrating blade 
microtome (Leica microsystems).  Sections were incubated for 2h at room temperature in TBS+ 1% Triton-X + 
10% donkey serum. Samples were incubated for 72h at 4°C with primary antibodies, followed by 2h incubation 
at RT with secondary antibodies. All images were captured on a Zeiss confocal microscope (Carl Zeiss 
Microscopy, Thornwood, NY, USA). Antibodies are listed in Supplementary Table 2.  For quantification of MNs 
and microglia, lumbar spinal cords were sectioned 40 µm thick from the end of thoracic level 14 to sacral level 
1.  For MN counts lumbar spinal cord sections were selected every 5th section from the first identifiable L1 
section through L6 and sections were selected every 8th section for microglial quantification. 
Statistical Analyses 
For all statistical tests Graph Pad Prism 6 software (La Jolla, CA) was used.  Statistical analyses of 
mean differences between groups was performed by either Student’s t-test, one or two-way ANOVA, followed 
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by a Bonferroni post hoc analysis depending on the number of variables and time-points in each experiment.  
All p-values and n values are indicated in figure legends.   
 
Acknowledgements:  This work was funded by US National Institutes of Health (NIH) R01 NS644912, Project 
A.L.S. and Packard Center for ALS Research (P2ALS) and Helping Link Foundation. A.F. is supported by 
NINDS T32NS077984 Training in Neuromuscular Disease and L.F. is supported by a Marie Curie Fellowship.   
 
REFERENCES 
Alexianu, M.E., Kozovska, M., and Appel, S.H. (2001). Immune reactivity in a mouse model of familial ALS 
correlates with disease progression. Neurology 57, 1282–1289. 
Almer, G., Kikuchi, H., Teismann, P., and Przedborski, S. (2006). Is prostaglandin E(2) a pathogenic factor in 
amyotrophic lateral sclerosis? Ann Neurol. 59, 980–983. 
Beattie, E.C., Stellwagen, D., Morishita, W., Bresnahan, J.C., Ha, B.K., Zastrow, Von, M., Beattie, M.S., and 
Malenka, R.C. (2002). Control of synaptic strength by glial TNFalpha. Science 295, 2282–2285. 
Beers, D.R., Henkel, J.S., Xiao, Q., Zhao, W., Wang, J., Yen, A.A., Siklós, L., McKercher, S.R., and Appel, 
S.H. (2006). Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral 
sclerosis. Proc. Natl. Acad. Sci. U.S.a. 103, 16021–16026. 
Beers, D.R., Henkel, J.S., Zhao, W., Wang, J., Huang, A., Wen, S., Liao, B., and Appel, S.H. (2011a). 
Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with 
disease progression in patients with amyotrophic lateral sclerosis. Brain 134, 1293–1314. 
Beers, D.R., Zhao, W., Liao, B., Kano, O., Wang, J., Huang, A., Appel, S.H., and Henkel, J.S. (2011b). 
Neuroinflammation modulates distinct regional and temporal clinical responses in ALS mice. Brain Behavior 
and Immunity 25, 1025–1035. 
Boillee, S., Yamanaka, K., Lobsiger, C.S., Copeland, N.G., Jenkins, N.A., Kassiotis, G., Kollias, G., and 
Cleveland, D.W. (2006). Onset and progression in inherited ALS determined by motor neurons and microglia. 
Science 312, 1389–1392. 
Bracchi-Ricard, V., Brambilla, R., Levenson, J., Hu, W.-H., Bramwell, A., Sweatt, J.D., Green, E.J., and 
Bethea, J.R. (2008). Astroglial nuclear factor-kappaB regulates learning and memory and synaptic plasticity in 
female mice. J Neurochem 104, 611–623. 
Butovsky, O., Siddiqui, S., Gabriely, G., Lanser, A.J., Dake, B., Murugaiyan, G., Doykan, C.E., Wu, P.M., Gali, 
R.R., Iyer, L.K., et al. (2012). Modulating inflammatory monocytes with a unique microRNA gene signature 
ameliorates murine ALS. J. Clin. Invest. 122, 3063–3087. 
Chiu, I.M., Morimoto, E.T.A., Goodarzi, H., Liao, J.T., O’Keeffe, S., Phatnani, H.P., Muratet, M., Carroll, M.C., 
Levy, S., Tavazoie, S., et al. (2013). A neurodegeneration-specific gene-expression signature of acutely 
isolated microglia from an amyotrophic lateral sclerosis mouse model. Cell Rep 4, 385–401. 
	  
	  
20	  
	  
Clement, A.M., Nguyen, M.D., Roberts, E.A., Garcia, M.L., Boillee, S., Rule, M., McMahon, A.P., Doucette, W., 
Siwek, D., Ferrante, R.J., et al. (2003). Wild-type nonneuronal cells extend survival of SOD1 mutant motor 
neurons in ALS mice. Science 302, 113–117. 
Crosio, C., Valle, C., Casciati, A., Iaccarino, C., and Carrì, M.T. (2011a). Astroglial inhibition of NF-κB does not 
ameliorate disease onset and progression in a mouse model for amyotrophic lateral sclerosis (ALS). PLoS 
ONE 6, e17187. 
Crosio, C., Valle, C., Casciati, A., Iaccarino, C., and Carrì, M.T. (2011b). Astroglial Inhibition of NF-κB Does 
Not Ameliorate Disease Onset and Progression in a Mouse Model for Amyotrophic Lateral Sclerosis (ALS). 
PLoS ONE 6, e17187. 
Deng, L., Zhou, J.-F., Sellers, R.S., Li, J.-F., Nguyen, A.V., Wang, Y., Orlofsky, A., Liu, Q., Hume, D.A., 
Pollard, J.W., et al. (2010). A novel mouse model of inflammatory bowel disease links mammalian target of 
rapamycin-dependent hyperproliferation of colonic epithelium to inflammation-associated tumorigenesis. Am. J. 
Pathol. 176, 952–967. 
Di Giorgio, F.P., Boulting, G.L., Bobrowicz, S., and Eggan, K.C. (2008). Human embryonic stem cell-derived 
motor neurons are sensitive to the toxic effect of glial cells carrying an ALS-causing mutation. Cell Stem Cell 3, 
637–648. 
Di Giorgio, F.P., Carrasco, M.A., Siao, M.C., Maniatis, T., and Eggan, K. (2007). Non–cell autonomous effect 
of glia on motor neurons in an embryonic stem cell–based ALS model. Nat Neurosci 10, 608–614. 
Emmanouil, M., Taoufik, E., Tseveleki, V., Vamvakas, S.-S., Tselios, T., Karin, M., Lassmann, H., and Probert, 
L. (2009). Neuronal I kappa B kinase beta protects mice from autoimmune encephalomyelitis by mediating 
neuroprotective and immunosuppressive effects in the central nervous system. The Journal of Immunology 
183, 7877–7889. 
Erblich, B., Zhu, L., Etgen, A.M., Dobrenis, K., and Pollard, J.W. (2011). Absence of colony stimulation factor-1 
receptor results in loss of microglia, disrupted brain development and olfactory deficits. PLoS ONE 6, e26317. 
Foust, K.D., Nurre, E., Montgomery, C.L., Hernandez, A., Chan, C.M., and Kaspar, B.K. (2008). Intravascular 
AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 27, 59–65. 
Foust, K.D., Salazar, D.L., Likhite, S., Ferraiuolo, L., Ditsworth, D., Ilieva, H., Meyer, K., Schmelzer, L., Braun, 
L., Cleveland, D.W., et al. (2013). Therapeutic AAV9-mediated Suppression of Mutant SOD1 Slows Disease 
Progression and Extends Survival in Models of Inherited ALS. Molecular Therapy. 
Ghosh, S., and Karin, M. (2002). Missing pieces in the NF-kappaB puzzle. Cell 109 Suppl, S81–S96. 
Gowing, G., Dequen, F., Soucy, G., and Julien, J.-P. (2006). Absence of tumor necrosis factor-alpha does not 
affect motor neuron disease caused by superoxide dismutase 1 mutations. Journal of Neuroscience 26, 
11397–11402. 
Gutierrez, H. (2005). NF- B signalling regulates the growth of neural processes in the developing PNS and 
CNS. Development 132, 1713–1726. 
Haidet-Phillips, A.M., Hester, M.E., Miranda, C.J., Meyer, K., Braun, L., Frakes, A., Song, S., Likhite, S., 
Murtha, M.J., Foust, K.D., et al. (2011). Astrocytes from familial and sporadic ALS patients are toxic to motor 
neurons. Nat Biotechnol 29, 824–828. 
Hall, E.D., Oostveen, J.A., and Gurney, M.E. (1998). Relationship of microglial and astrocytic activation to 
	  
	  
21	  
	  
disease onset and progression in a transgenic model of familial ALS. Glia 23, 249–256. 
Hayden, M.S., and Ghosh, S. (2008). Shared principles in NF-kappaB signaling. Cell 132, 344–362. 
Henkel, J.S., Beers, D.R., Zhao, W., and Appel, S.H. (2009). Microglia in ALS: the good, the bad, and the 
resting. J Neuroimmune Pharmacol 4, 389–398. 
Ismail, A., Cooper-Knock, J., Highley, J.R., Milano, A., Kirby, J., Goodall, E., Lowe, J., Scott, I., 
Constantinescu, C.S., Walters, S.J., et al. (2013). Concurrence of multiple sclerosis and amyotrophic lateral 
sclerosis in patients with hexanucleotide repeat expansions of C9ORF72. Journal of Neurology, Neurosurgery 
& Psychiatry 84, 79–87. 
Kaltschmidt, B., and Kaltschmidt, C. (2009). NF-kappaB in the nervous system. Cold Spring Harb Perspect Biol 
1, a001271. 
Kaltschmidt, B., Ndiaye, D., Korte, M., Pothion, S., Arbibe, L., Prüllage, M., Pfeiffer, J., Lindecke, A., Staiger, 
V., Israël, A., et al. (2006). NF-kappaB regulates spatial memory formation and synaptic plasticity through 
protein kinase A/CREB signaling. Molecular and Cellular Biology 26, 2936–2946. 
Kawamata, T., Akiyama, H., Yamada, T., and McGeer, P.L. (1992). Immunologic reactions in amyotrophic 
lateral sclerosis brain and spinal cord tissue. Am. J. Pathol. 140, 691–707. 
Kigerl, K.A., Gensel, J.C., Ankeny, D.P., Alexander, J.K., Donnelly, D.J., and Popovich, P.G. (2009). 
Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or 
regeneration in the injured mouse spinal cord. Journal of Neuroscience 29, 13435–13444. 
Lerman, B.J., Hoffman, E.P., Sutherland, M.L., Bouri, K., Hsu, D.K., Liu, F.-T., Rothstein, J.D., and Knoblach, 
S.M. (2012). Deletion of galectin-3 exacerbates microglial activation and accelerates disease progression and 
demise in a SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Brain Behav 2, 563–575. 
Li, Z.-W., Omori, S.A., Labuda, T., Karin, M., and Rickert, R.C. (2003). IKK beta is required for peripheral B cell 
survival and proliferation. J. Immunol. 170, 4630–4637. 
Magness, S.T., Jijon, H., van Houten Fisher, N., Sharpless, N.E., Brenner, D.A., and Jobin, C. (2004). In vivo 
pattern of lipopolysaccharide and anti-CD3-induced NF-kappa B activation using a novel gene-targeted 
enhanced GFP reporter gene mouse. J. Immunol. 173, 1561–1570. 
Mantovani, S., Garbelli, S., Pasini, A., Alimonti, D., Perotti, C., Melazzini, M., Bendotti, C., and Mora, G. (2009). 
Immune system alterations in sporadic amyotrophic lateral sclerosis patients suggest an ongoing 
neuroinflammatory process. Journal of Neuroimmunology 210, 73–79. 
Marchetto, M.C.N., Muotri, A.R., Mu, Y., Smith, A.M., Cezar, G.G., and Gage, F.H. (2008). Non-cell-
autonomous effect of human SOD1 G37R astrocytes on motor neurons derived from human embryonic stem 
cells. Cell Stem Cell 3, 649–657. 
Maruyama, H., Morino, H., Ito, H., Izumi, Y., Kato, H., Watanabe, Y., Kinoshita, Y., Kamada, M., Nodera, H., 
Suzuki, H., et al. (2011). Mutations of optineurin in amyotrophic lateral sclerosis. Nature 465, 223–226. 
Mattson, M.P., and Meffert, M.K. (2006). Roles for NF-κB in nerve cell survival, plasticity, and disease. Cell 
Death and Differentiation 13, 852–860. 
Miranda, C.J., Braun, L., Jiang, Y., Hester, M.E., Zhang, L., Riolo, M., Wang, H., Rao, M., Altura, R.A., and 
Kaspar, B.K. (2012). Aging brain microenvironment decreases hippocampal neurogenesis through Wnt-
	  
	  
22	  
	  
mediated survivin signaling. Aging Cell 11, 542–552. 
Mosser, D.M., and Edwards, J.P. (2008). Exploring the full spectrum ofmacrophage activation. Nature Reviews 
Immunology 8, 958–969. 
Moussaud, S., and Draheim, H.J. (2010). A new method to isolate microglia from adult mice and culture them 
for an extended period of time. Journal of Neuroscience Methods 187, 243–253. 
Nagai, M., Re, D.B., Nagata, T., Chalazonitis, A., Jessell, T.M., Wichterle, H., and Przedborski, S. (2007). 
Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat 
Neurosci 10, 615–622. 
Nguyen, M.D., Julien, J.P., and Rivest, S. (2001). Induction of proinflammatory molecules in mice with 
amyotrophic lateral sclerosis: no requirement for proapoptotic interleukin-1beta in neurodegeneration. Ann 
Neurol. 50, 630–639. 
Norden, D.M., and Godbout, J.P. (2013). Review: Microglia of the aged brain: primed to be activated and 
resistant to regulation. Neuropathol Appl Neurobiol 39, 19–34. 
Park, J.M., Greten, F.R., Li, Z.-W., and Karin, M. (2002). Macrophage apoptosis by anthrax lethal factor 
through p38 MAP kinase inhibition. Science 297, 2048–2051. 
Philips, T., and Robberecht, W. (2011). Neuroinflammation in amyotrophic lateral sclerosis: role of glial 
activation in motor neuron disease. Lancet Neurol 10, 253–263. 
Ransohoff, R.M., and Perry, V.H. (2009). Microglial physiology: unique stimuli, specialized responses. Annu. 
Rev. Immunol. 27, 119–145. 
Rosen, D.R., Siddique, T., Patterson, D., Figlewicz, D.A., Sapp, P., Hentati, A., Donaldson, D., Goto, J., 
O'Regan, J.P., and Deng, H.X. (1993). Mutations in Cu/Zn superoxide dismutase gene are associated with 
familial amyotrophic lateral sclerosis. Nature 362, 59–62. 
Ruocco, M.G., Maeda, S., Park, J.M., Lawrence, T., Hsu, L.-C., Cao, Y., Schett, G., Wagner, E.F., and Karin, 
M. (2005). IkappaB kinase (IKK)beta, but not IKKalpha, is a critical mediator of osteoclast survival and is 
required for inflammation-induced bone loss. J. Exp. Med. 201, 1677–1687. 
Sako, W., Ito, H., Yoshida, M., Koizumi, H., Kamada, M., Fujita, K., Hashizume, Y., Izumi, Y., and Kaji, R. 
(2012). Nuclear factor κ B expression in patients with sporadic amyotrophic lateral sclerosis and hereditary 
amyotrophic lateral sclerosis with optineurin mutations. Clin. Neuropathol. 31, 418–423. 
Sasmono, R.T., and Williams, E. (2012). Generation and characterization of MacGreen mice, the Cfs1r-EGFP 
transgenic mice. Methods Mol. Biol. 844, 157–176. 
Sasmono, R.T., Oceandy, D., Pollard, J.W., Tong, W., Pavli, P., Wainwright, B.J., Ostrowski, M.C., Himes, 
S.R., and Hume, D.A. (2003). A macrophage colony-stimulating factor receptor-green fluorescent protein 
transgene is expressed throughout the mononuclear phagocyte system of the mouse. Blood 101, 1155–1163. 
Son, M., Fathallah-Shaykh, H.M., and Elliott, J.L. (2001). Survival in a transgenic model of FALS is 
independent of iNOS expression. Ann Neurol. 50, 273. 
Swarup, V., Phaneuf, D., Dupré, N., Petri, S., Strong, M., Kriz, J., and Julien, J.-P. (2011). Deregulation of 
TDP-43 in amyotrophic lateral sclerosis triggers nuclear factor κB-mediated pathogenic pathways. Journal of 
Experimental Medicine 208, 2429–2447. 
	  
	  
23	  
	  
Taoufik, E., Tseveleki, V., Chu, S.Y., Tselios, T., Karin, M., Lassmann, H., Szymkowski, D.E., and Probert, L. 
(2011). Transmembrane tumour necrosis factor is neuroprotective and regulates experimental autoimmune 
encephalomyelitis via neuronal nuclear factor-kappaB. Brain 134, 2722–2735. 
Turner, M.R., Cagnin, A., Turkheimer, F.E., Miller, C.C.J., Shaw, C.E., Brooks, D.J., Leigh, P.N., and Banati, 
R.B. (2004). Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an 
[11C](R)-PK11195 positron emission tomography study. Neurobiology of Disease 15, 601–609. 
Uranishi, H., Tetsuka, T., Yamashita, M., Asamitsu, K., Shimizu, M., Itoh, M., and Okamoto, T. (2001). 
Involvement of the pro-oncoprotein TLS (translocated in liposarcoma) in nuclear factor-kappa B p65-mediated 
transcription as a coactivator. J. Biol. Chem. 276, 13395–13401. 
Vallabhapurapu, S., and Karin, M. (2013). Regulation and function of NF-kappaB transcription factors in the 
immune system. Annu. Rev. Immunol. 27, 693–733. 
Wang, C.Y., Cusack, J.C., Liu, R., and Baldwin, A.S. (1999). Control of inducible chemoresistance: enhanced 
anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 5, 412–417. 
Wichterle, H., Lieberam, I., Porter, J.A., and Jessell, T.M. (2002). Directed differentiation of embryonic stem 
cells into motor neurons. Cell 110, 385–397. 
Xiao, Q., Zhao, W., Beers, D.R., Yen, A.A., Xie, W., Henkel, J.S., and Appel, S.H. (2007). Mutant SOD1 
G93Amicroglia are more neurotoxic relative to wild-type microglia. J Neurochem 102, 2008–2019. 
Yamanaka, K., Chun, S.J., Boillee, S., Fujimori-Tonou, N., Yamashita, H., Gutmann, D.H., Takahashi, R., 
Misawa, H., and Cleveland, D.W. (2008). Astrocytes as determinants of disease progression in inherited 
amyotrophic lateral sclerosis. Nat Neurosci 11, 251–253. 
Zhao, W., Xie, W., Le, W., Beers, D.R., He, Y., Henkel, J.S., Simpson, E.P., Yen, A.A., Xiao, Q., and Appel, 
S.H. (2004). Activated microglia initiate motor neuron injury by a nitric oxide and glutamate-mediated 
mechanism. J. Neuropathol. Exp. Neurol. 63, 964–977. 
Zhuo, L., Theis, M., Alvarez-Maya, I., Brenner, M., Willecke, K., and Messing, A. (2001). hGFAP-cre transgenic 
mice for manipulation of glial and neuronal function in vivo. Genesis 31, 85–94. 
FIGURE LEGENDS 
 
Figure 1. The classical NF-κB pathway is activated with disease progression in the SOD1-G93A mouse 
model and astroglial NF-κB inhibition does not confer neuroprotection.  
(A and B) Immunoblot (A) and fold changes (B) of lumbar spinal cord protein isolated from WT mice at 120 
days and from SOD1-G93A female mice at pre-symptomatic (Pre), onset (Ons), symptomatic (Sym), late-
symptomatic (LSym), and end-stage (ES).  phospho-p65 (top) total p65 (middle) and Actin (bottom).  n=3.  
Additional data shown in Supplemental Figure S1.  
(C)  Immunoblot of protein isolated from astrocytes obtained from late-sym SOD1-G93A and WT littermates. 
(D and E) Kaplan-Meier survival curve (D) of SOD1-G93A mice injected with AAV9-IκBα-SR (median 
survival=128, n=16) and non-injected controls (median survival=136.5, n=14) and motor performance on 
accelerating rotarod test (E).  
(F and G)  Kaplan-Meier survival curve (F) of SOD1-G93A; IKKβf/f; GFAP-cre- (median survival=154, n=10) 
and SOD1-G93A; IKKβf/f; GFAP-cre+ mice (median survival=149, n=14) and motor performance on 
accelerating rotarod test (G). 
All band intensities were normalized to p65/Actin. 
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Error bars represent s.e.m.  *, P<0.05, **, P<0.01. 
 
 
Figure 2. NF-κB activation occurs predominately in microglia in the SOD1-G93A mouse model 
(A and B) Representative high magnification images of NF-κB-GFP-positive cells (green) in the lumbar ventral 
horn of late-symptomatic NF-κB EGFP;SOD1-G93A mice.  Most predominant GFP+ cells (A) also positive for 
microglial marker Iba1+ (red).  Other GFP+ cells positive for astrocyte maker GFAP (blue) Scale bar = 5 
microns (A) 20 microns (B). 
C) Immunoblot of protein isolated from primary microglia obtained from late-sym SOD1-G93A mice and WT 
littermates. Fold change determined by phospho-p65 band intensity normalized to p65/Actin.   
(D)  Immunohistochemistry of lumbar ventral horn of WT; NF-κB -GFP at 120 days, and SOD1-G93A; NF-κB -
GFP mice pre-sym, onset, sym, late-sym, and ES. NF-κB activation shown by NF-κB EGFP (green) and 
microglia and vasculature shown by tomato lectin (red).  Scale bar= 50 microns. 
(E)  Quantification of GFP+ cells co-localizing with tomato lectin in lumbar spinal cord sections of SOD1-G93A; 
NF-κB -GFP mice.  
Error bars represent s.e.m. **, P<0.01, ****, P< 0.0001 
 
 
Figure 3. Adult SOD1-G93A microglia are toxic to MNs in vitro   
(A and B) Immunocytochemistry of WT and SOD1-G93A microglia for prototypic microglial markers Iba-1, 
CD11b, F4/80, and astrocytes (GFAP), oligodendrocyte precursors (NG2), and MNs (ChAT).  
Quantification per well (B).  DAPI (blue) Scale bar = 20 microns. 
(C) Flow cytometry of adult microglia for CD45 and CD11b.   
(D and E) Representative microscopic field (D) and quantification of well (E) of surviving Hb9-GFP+ MNs after 
3 days (72 hours) of co-culture with either WT or SOD1-G93A microglia that were not infected (black bars) 
or infected with Lv-RFP (dashed bars) or Lv-shRNA-SOD1 (white bars).  Scale bar = 200 microns 
(F) Quantification of human SOD1 protein in SOD1-G93A microglia infected with Lv-RFP and Lv-shRNA-SOD1 
determined by ELISA. 
Error bars represent s.e.m. ***, P< 0.001, ****, P<0.0001 
 
Figure 4. Adult SOD1-G93A microglia induce MN death in an NF-κB dependent mechanism in vitro.   
 
(A and B) Representative microscopic fields (A) and well counts (B) of Hb9-GFP+ MNs after 1 day (24 hours) 
and 3 days (72 hours) in co-culture with WT or SOD1-G93A microglia not infected (black bars), infected 
with Ad-RFP (dashed bars) or Ad-IκBα-SR (white bars).  MNs co-cultured with either WT; IKKβf/f or SOD1-
G93A; IKKβf/f  microglia infected with Ad-cre shown with dashed bars.  Scale bar = 200 microns  
 
(C and D) Quantification of TNF-α (C) and nitric oxide (D) in the co-culture medium by ELISA.   
(E) Quantification of phospho-p65 by ELISA from microglial-MN co-cultures.  Phospho-p65 normalized to total 
p65 determined by ELISA. 
(F) Luciferase assay of NF-κB activity in microglia.  Firefly luciferase normalized to renilla luciferase. 
Error bars represent s.e.m. ****, P< 0.0001, ***, P< 0.001 
 
 
Figure 5. SOD1-G93A microglia induce MN death in an NF-κB dependent mechanism in vivo. 
(A) Kaplan-Meier survival curve of SOD1-G93A; IKKβF/wt; CSF1R-cre- (n=22) and SOD1-G93A; IKKβF/wt; CSF-
1R-cre+ mice (n=25).  Median survival SOD1-G93A; IKKβF/wt; CSF1R-cre- = 133 days, SOD1-G93A; 
IKKβF/wt; CSF-1R-cre+=153 days.  Mean survival SOD1-G93A; IKKβF/wt; CSF1R-cre- =134.9±1.4 days, , 
SOD1-G93A; IKKβF/wt; CSF-1R-cre+=153.7±0.9 days, P<.0001 
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(B)  Disease onset determined by age at which peak weight was reached. SOD1-G93A; IKKβF/wt; CSF1R-cre-
reached onset at 102.8±1.1 days and SOD1-G93A; IKKβF/wt; CSF1R-cre+ mice reached onset at 101.1±1.3 
days. 
(C) Disease progression defined as time from disease onset to ES. SOD1-G93A; IKKβF/wt; CSF1R-cre- mean 
disease progression = 34.8±1.4 days and SOD1-G93A; IKKβF/wt; CSF1R-cre+ mean disease progression = 
51.1±1.7 days. 
(D) Immunoblot of lumbar spinal cord protein isolated from WT; IKKβF/wt; CSF1R-cre+, WT; IKKβF/wt; CSF1R-
cre-, and ES SOD1-G93A; IKKβF/wt; CSF1R-cre-, SOD1-G93A; IKKβF/wt CSF1R-cre+ mice probed for 
phospho-p65 (top), total p65, IKKβ, human SOD1 and Actin (bottom).  Fold change represents band 
intensities of phospho-p65 normalized to p65/Actin and IKKβ normalized to Actin.   
(E) Immunohistochemistry of Iba1-positive microglia (red) and GFAP-positive astrocytes (green) in the lumbar 
spinal cords of ES SOD1-G93A; IKKβF/wt CSF1R-cre-, and age-matched SOD1-G93A; IKKβf/wt CSF1R-
cre+, and WT IKKβf/wt CSF1R-cre+ littermates.  Scale bar = 200 microns  
(F and G) Quantification of GFAP and Iba-1 signal intensity in SOD1-G93A; IKKβF/wt CSF1R-cre- and age-
matched SOD1-G93A; IKKβf/wt CSF1R-cre+ immunohistochemistry in represented in (E).  
 
 
Figure 6. NF-κB inhibition in SOD1-G93A microglia impairs microglial activation to a pro-inflammatory, 
neurotoxic phenotype 
(A and B) Immunohistochemistry (A) and quantification (B) of CD68 (red) and Iba1 (green) cells in lumbar 
spinal cord of disease-matched ES SOD1-G93A; IKKβF/wt CSF1R-cre- and SOD1-G93A; IKKβF/wt CSF1R-
cre+ littermates.  Scale bar = 200 microns 
(C and D) Immunohistochemistry (C) and quantification (D) of iNOS (red) and Iba1 (green) cells in lumbar 
spinal cord of disease-matched ES SOD1-G93A; IKKβF/wt CSF1R-cre- and SOD1-G93A; IKKβF/wt CSF1R-
cre+ littermates. Scale bar = 20 microns 
(E and F)Immunohistochemistry (E) and quantification (F) of CD86 (red) and Iba1 (green) cells in lumbar spinal 
cord of disease-matched ES SOD1-G93A; IKKβF/wt CSF1R-cre- and SOD1-G93A; IKKβF/wt CSF1R-cre+ 
littermates.  Scale bar = 20 microns 
 
Figure 7.  NF-κB activation in wild-type microglia induces MN death 
(A and B) Representative microscopic fields (A) and counts (B) of Hb9-GFP+ MNs after 1 day (24 hours) and 3 
days (72 hours) in co-culture with WT microglia (white bar) or WT microglia with constitutively active IKKβ 
(IKKβCA) (black bar).  
(C) Quantification of NF-κB activation (phospho-p65), normalized to total p65, both determined by ELISA.  
(D) Immunoblot of lumbar spinal cord protein from WT and IKKβCA mice.  The blot was probed for p-p65 (top), 
IKKβ (top middle), p65 (bottom middle) and Actin (bottom).  p-p65 band intensities normalized to p65/Actin.  
Fold change determined by densitometry in Image J. 
(E) Immunohistochemistry of lumbar spinal cords of WT and IKKβCA littermates at 8 months.  Iba1-positive 
microglia (red), GFAP-positive astrocytes (blue), ChAT-positive MNs (green). Scale bar = 100 microns 
(F) Counts of ChAT+ MNs in ventral horn of lumbar spinal cord from 8-month old IKKβCA and WT littermates.  
(n=3) 
(G and H) Mass (G) and grip strength (H) of IKKβCA (n=6) and WT littermates (n=8). 
 
 
Figure 8.  The classical NF-κB pathway mediates microglial activation and MN death. 
(A)  Model of the mechanism by which SOD1-G93A microglia induce MN death in ALS.  The NF-κB pathway is 
initiated in SOD1-G93A microglia by a SOD1-G93A-dependent mechanism leading to microglial activation 
and subsequently, MN death via inflammatory pathways.  Inhibition of microglial NF-κB in ALS mice blocks 
microglial activation, down-regulates pro-inflammatory markers, and delays MN death. 
(B) Model of IKKβCA mice in which NF-κB is constitutively active only in myeloid cells.  Microglia in these mice 
exhibit a pro-inflammatory phenotype which induces MN death in a mutant SOD1-independent mechanism. 
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SUPPLEMENTAL FIGURES AND LEGENDS 
 
Figure S1.  The classical NF-κB pathway is activated in SOD1-G93A mice, related to Figure 1. 
(A) Electrophoretic mobility shift assay of total spinal cord nuclear extracts from 130 day old wild-
type mice and end-stage SOD1-G93A mice.  Free represents the probe free condition.  “+” 
represents positive control from IKKβCA mice. 
(B) Supershifts of nuclear extracts from SOD1-G93A sample #3 and #2.  Arrow shows 
supershifted band from p65 antibody.  “-“ indicates no antibody is added. 
(C) Immunoblot of lumbar spinal cord protein lysate from wild-type (n=2), late-stage (n=6), and 
end-stage (n=6) SOD1-G93A mice.  The blot was probed for phospho-p65 and reprobed for 
total p65 (middle) and Actin (bottom) as loading controls. 
(D) Fold change of the immunoblot in (C) determined using Image J to measure band intensities of 
phospho-p65 normalized to p65/Actin.  Phospho-p65 is upregulated by 13.4 ± 1.6 fold 
compared to wild-type at the late-symptomatic stage and by 14.1 ± 4.8 fold at end stage. 
Error bars represent s.e.m. 
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Figure S2. NF-κB inhibition in astrocytes does not confer neuroprotection in vitro or in vivo in 
the SOD1-G93A mouse model, related to Figure 1.   
(A) Quantification of surviving Hb9-GFP+ motor neurons per well during 6-day co-culture with wild-
type (white) or SOD1-G93A astrocytes infected with Ad-RFP (black) or Ad-IκBα-SR (gray).  (n=3)  
(B) Quantification of phospho-p65 by ELISA in wild-type and SOD1-G93A astrocytes infected by Ad-
RFP or Ad-IκBα-SR and stimulated with 10ng/mL TNF-α for 12 hours. 
(C and D) Representative images of GFAP-cre-negative and positive Rosa26-StopFlox-CAG-tdTomato 
mice.  Native RFP fluorescence was analyzed for co-localization with immunohistochemical 
markers for (C) astrocytes (GFAP and EAAT2), microglia (Iba1), and (B) motor neurons (ChAT).  
Scale bar = 100 microns (top) 50 microns (bottom) 
(E) Immunoblot of lumbar spinal cord protein isolated from WT; IKKβf/f; GFAP-cre-, WT; IKKβf/f; 
GFAP-cre+, and symptomatic SOD1-G93A; IKKβf/f; GFAP-cre-, SOD1-G93A; IKKβf/f; GFAP-cre+ 
mice probed for phospho-p65 (top) and Actin (bottom) confirm reduction in NF-κB activation in 
cre+ mice.  Fold change represents band intensities of phospho-p65/Actin determined by ImageJ. 
Error bars represent s.e.m. * , P< 0.05; **, P<0.01; **** , P< 0.0001 
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Figure S3.  SOD1-G93A neonatal microglia are not toxic to Hb9-GFP+ motor neurons 
compared to wild-type microglia, related to Figure 4.  Quantification of surviving Hb9-GFP+ motor 
neurons per well during co-culture with wild-type (white) or SOD1-G93A microglia (black).  Error bars 
represent s.e.m. 
 
 
Movie S1.  Live-imaging of co-culture with Hb9-GFP+ motor neurons (green) and wild-type microglia 
(red), related to Figure 4.   
 
Movie S2.  Live-imaging of co-culture with Hb9-GFP+ motor neurons (green) and SOD1-G93A 
microglia (red), related to Figure 4.     
 
Movie S3. Live-imaging of co-culture with Hb9-GFP+ motor neurons (green) and wild-type microglia 
overexpressing IκBα-SR (not fluorescently labeled), related to Figure 4.    
 
Movie S4.  Live-imaging of co-culture with Hb9-GFP+ motor neurons (green) and SOD1-G93A 
microglia overexpressing IκBα-SR (not fluorescently labeled), related to Figure 4.    
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Figure S4.  CSF-1R-cre is selectively expressed in microglia in the CNS, related to Figure 5.    
(A and B) Representative images of CSF1R-cre-negative and positive Rosa26-StopFlox-CAG-
tdTomato mice.  Native RFP fluorescence was analyzed for co-localization with 
immunohistochemical markers for (A) microglia (Iba-1) and astrocytes (GFAP), and (B) motor 
neurons (ChAT).  Scale bar= 100 microns (top) and 10 microns (bottom). 
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(C)  Immunohistochemical analysis of end-stage SOD1-G93A; IKKβF/wt; CSF1R-cre negative and 
positive mice for IKKβ (red) and IKKγ (green) and tomato lectin (blue). Scale bar = 50 microns 
 
Movie S5.  Movie of representative SOD1-G93A; IKKβf/wt; CSF-1R-cre+ mouse compared to cre-
negative littermate.  Related to Figure 5. 
 
Movie S6.  Live-imaging of co-culture with Hb9-GFP+ motor neurons (green) and wild-type microglia 
expressing constitutively active IKKβ (not fluorescently labeled). Related to Figure 7. 
 
Figure S5.  NF-κB activation in wild-type microglia in vitro induces microglial activation to a 
pro-inflammatory, neurotoxic phenotype, related to Figure 7. 
(A) Luciferase assay of NF-κB activity in wild-type (white bar) and IKKβCA (black bar) microglia.  
Firefly luciferase was normalized to renilla luciferase. 
(B and C) Quantification of TNF-α (B) and nitric oxide (C) in the co-culture medium by ELISA.  Nitric 
oxide measured indirectly by sum of nitrate and nitrite.  
Error bars represent s.e.m. * , P< 0.05, ** , P< 0.01 
 
  
	  
	  
39	  
	  
 
 
 
Figure S6.  NF-κB activation in wild-type microglia in vivo induces microglial activation to a 
pro-inflammatory, neurotoxic phenotype, related to Figure 7. 
(A) Immunohistochemistry of CD68 (red) and Iba1 (green) cells in lumbar spinal cord of WT and 
IKKβCA littermates at 4 and 8 months. Scale bar = 50 microns 
(B) Immunohistochemistry of CD86 (red) and Iba1 (green) cells in lumbar spinal cord of WT and 
IKKβCA littermates at 4 and 8 months. Scale bar = 20 microns 
(C) Immunohistochemistry of iNOS (red) and Iba1 (green) cells in lumbar spinal cord of WT and 
IKKβCA littermates at 8 months. Scale bar = 10 microns 
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Supplemental Table 1.  List of primers 
Genotyping	  qualitative	  PCR	  
	   	  Gene	   Forward	  Primer	  (5'-­‐3')	   Reverse	  Primer	  (5'-­‐3')	  
	  human	  SOD1	   CAT	  CAG	  CCC	  TAA	  TCC	  ATC	  TGA	   CGC	  GAC	  TAA	  CAA	  TCA	  AAG	  TGA	  
	  Control	  for	  SOD1	  
reaction	  
CTA	  GGC	  CAC	  AGA	  ATT	  GAA	  AGA	  
TCT	  
GTA	  GGT	  GGA	  AAT	  TCT	  AGC	  ATC	  
ATC	  C	  
	  IKKβ	   GTC	  ATT	  TCC	  ACA	  GCC	  CTG	  TGA	  	   CCT	  TGT	  CCT	  ATA	  GAA	  GCA	  CAA	  
	  iCre	   CAGGGCCTTCTCCACACCAGC	   CTGGCTGTGAAGACCATC	  
	  Cre	   GGACATGTTCAGGGATCGCCAGGCG	   CGACGATGAAAGCATGTTTAGCTG	  
	  
eGFP	  
GAG	  CTG	  AAG	  GGC	  ATC	  GAC	  TTC	  
AAG	  
GGA	  CTG	  GGT	  GCT	  CAG	  GTA	  GTG	  
G	  
	  negative	  for	  eGFP	   TCAGGCCCACCTAGTCAGAT	   AAAGCGGTCTGAGGAGGAA	  
	  tdTomato	   CTG	  TTC	  CTG	  TAC	  GGC	  ATG	  G	   GGC	  ATT	  AAA	  GCA	  GCG	  TAT	  CC	  
	  negative	  for	  tdTomato	   AAG	  GGA	  GCT	  GCA	  GTG	  GAG	  TA	   CCG	  AAA	  ATC	  TGT	  GGG	  AAG	  TC	  
	  	  	   	  	   	  	   	  	  
Copy	  Number	  real	  time	  PCR	  	   	  	   	  	  
Primer	   5'	  label	   Sequence	  5'	  -­‐-­‐>	  3'	   3'	  Label	  
Transenic	  Probe	   6-­‐FAM	   CTG	  CAT	  CTG	  GTT	  CTT	  GCA	  AAA	  CAC	  CA	  
Zen	  probe	  
with	  Iowa	  
Black	  
Internal	  Positive	  
Control	  
Forward	  
-­‐	   CAC	  GTG	  GGC	  TCC	  AGC	  ATT	   -­‐	  
Internal	  Positive	  
Control	  
Reverse	  
-­‐	   TCA	  CCA	  GTC	  ATT	  TCT	  GCC	  TTT	  G	   -­‐	  
hSOD1	  Forward	   -­‐	   GGG	  AAG	  CTG	  TTG	  TCC	  CAA	  G	   -­‐	  
hSOD1	  Reverse	   -­‐	   CAA	  GGG	  GAG	  GTA	  AAA	  GAG	  AGC	   -­‐	  
Internal	  Control	  Probe	   Cy5	   CCA	  ATG	  GTC	  GGG	  CAC	  TGC	  TCA	  A	   Black	  Hole	  Quencher	  2	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Supplemental Table 2.  List of antibodies 
Western	  blot	  
	   	  Antibody	   Dilution	   Vendor	  
Phospho-­‐p65	   1:500	   Cell	  Signaling	  
p65	   1:500	   Cell	  Signaling	  
Beta-­‐Actin	   1:1000	   Cell	  Signaling	  
IKK-­‐beta	   1:125	   Imgenex	  
Immunohistochemistry	  
	  Antibody	   Dilution	   Vendor	  
GFP	   1:400	   Abcam	  
Tomato	  Lectin	   1:300	   Vector	  Laboratories	  
GFAP	   1:500	   Abcam	  
Iba-­‐1	   1:400	   Wako	  
CD68	   1:100	   AbDserotec	  
CD86	   1:100	   Millipore	  
iNOS	   1:100	   Sigma	  
IKK-­‐gamma	   1:100	   Cell	  Signaling	  
IKK-­‐beta	   1:100	   Imgenex	  
Immunocytochemistry	  
	  Antibody	   Dilution	   Vendor	  
CD11b	   1:200	   AbDserotec	  
F4/80	   1:100	   AbDserotec	  
NG2	   1:200	   Millipore	  
ChAT	   1:100	   Millipore	  
Iba-­‐1	   1:500	   Wako	  
GFAP	   1:200	   Abcam	  
Flow	  
Cytometry	  
	   	  Antibody	   Dilution	   Vendor	  
APC-­‐CD11b	   1:50	   eBiosciences 
PE-­‐CD45	   1:25	   eBiosciences 
EMSA	  supershift	  and	  nuclear	  western	  blots	  
p65	   1:1000	   Santa	  Cruz	  Biotechnology	  
p50	   1:1000	   Santa	  Cruz	  Biotechnology	  
c-­‐Rel	   1:1000	   Santa	  Cruz	  Biotechnology	  
Rel-­‐B	   1:1000	   Santa	  Cruz	  Biotechnology	  
IgG	   1:1000	   	  Santa	  Cruz	  Biotechnology	  
 
Transgenic mice 
All procedures were performed in accordance with the NIH Guidelines on the care and use of 
vertebrate animals and approved by the Institutional Animal Care and Use Committee of the 
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Research Institute at Nationwide Children’s Hospital. Animals were housed under light:dark (12:12 h) 
cycle and provided with food and water ad libitum.  Transgenic female B6SJ/L(SOD1-G93A)1Gur/J 
mice and non-transgenic littermates (Jackson Laboratories) were utilized for time course immunoblot 
studies and primary cell isolations.  Transgenic male B6SJ/L(SOD1-G93A)1Gur/J mice were used for 
breeding with other transgenic lines.  SOD1 transgene copy number was confirmed by real time PCR.  
SOD1-G93A-NFκBEGFP reporter mice were generated by breeding SOD1-G93A mice to C57BL/6 
NFκBEGFP mice (Christian Jobin) (Magness et al., 2004).  SOD1-G93A; hGFAP-cre; IKKβflox/flox were 
generated by breeding SOD1-G93A mice to FVB hGFAP-cre (Jackson Labs) mice that had been 
crossed to C57BL/6 IKKβflox/flox mice (Li et al., 2003). SOD1-G93A; CSF-1R-icre; IKKβflox/wt were 
generated by breeding SOD1-G93A mice to C57BL/6 CSF-1R-cre mice (Deng et al., 2010) that had 
been bred to IKKβflox/flox mice.  CSF1R-cre; IKKβCA were generated my breeding CSF-1R cre mice to 
C57BL/6 Rosa26-StopFloxIKKβCA mice (Jackson Labs).  Cre specificity was confirmed by crossing 
cre lines to C57BL/6 Rosa26-StopFlox-CAG-tdTomato (Jackson Labs) mice and assessed for 
tdTomato expression by immunohistochemistry.  Genotypes were determined by qualitative PCR 
using the primers in Supplementary Table 1. 
Disease scoring and behavior analysis 
Mice were classified as “pre-symtomatic” when they displayed no clinical symptoms of disease 
and had not reached peak weight.  “Onset” was determined at the stage mice reach peak body 
weight.  The “symptomatic” stage was determined when mice had lost 10% of their body weight and 
displayed motor impairment tremors or impaired hindlimb splay reflex.  The “late-symptomatic” stage 
was determined when mice experienced pronounced hindlimb paralysis, but could reach food and 
water using forelimbs.  “End-stage” was determined when animals could no longer “right” themselves 
within 30 seconds after the animal was placed on its back. 
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Testing of motor function using a rotarod device (Columbus Instruments, Columbus, OH) 
began at 50 days of age. Each session consisted of three trials that were averaged on the elevated 
accelerating rotarod beginning at 5 r.p.m./minute measuring the time the mouse was able to remain 
on the rod.  Grip strength measurements for hindlimb were tested weekly using a grip strength meter 
(Columbus Instruments). Each session consisted of three tests per animal and values were averaged.  
 Immunoblot analysis  
Cells and tissues were homogenized in Tissue Protein Extraction Reagent (Pierce) with EDTA, 
Complete protease inhibitor (Roche) and Phospho-STOP (Roche). The samples were run on 
NuPAGE Novex 4-12% Bis-Tris polyacrilamide gels and transferred to a PVDF membrane (Life 
Technologies). Blots were blocked in 5% milk powder, 0.5% BSA in PBS-Tween for 1h, and then 
incubated for overnight at 4°C with primary antibody.  Bound primary antibody was detected by 
horseradish peroxidase conjugated secondary antibody followed by chemiluminescence detection 
(ECL Western Blot Substrate, Pierce).  Antibodies are listed in Supplementary Table 2. 
Immunohistochemistry 
Animals were deeply anesthetized with a lethal dose of Xylazene/Ketamine and perfused 
transcardially with saline, then 4% paraformaldehyde.  Spinal cords were sectioned 40 µm thick using 
a vibrating blade microtome (Leica microsystems).  Sections were incubated for 2h at room 
temperature in TBS+ 1% Triton-X + 10% donkey serum. Samples were incubated for 72h at 4°C with 
primary antibodies, followed by 2h incubation at RT with secondary antibodies. All images were 
captured on a Zeiss confocal microscope (Carl Zeiss Microscopy, Thornwood, NY, USA). Antibodies 
are listed in Supplementary Table 2.  For quantification of MNs and microglia, lumbar spinal cords 
were sectioned 40 µm thick from the end of thoracic level 14 to sacral level 1.  For MN counts lumbar 
spinal cord sections were selected every 5th section from the first identifiable L1 section through L6 
and sections were selected every 8th section for microglial quantification. 
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Electrophoretic mobility shift assays (EMSA) and nuclear western blots 
EMSA and supershift analyses were performed on whole spinal cord nuclear lysates as 
previously described (Dahlman and Guttridge, 2012).  Nuclear westerns were performed using the 
same nuclear lysates as used for the EMSAs.  The antibodies against p65, p60, c-Rel, and RelB are 
listed in Supplementary Table 1.   
Isolation and culture of adult primary astrocytes 
Adult astrocyte cultures from brains of SOD1-G93A and wild-type littermates were prepared 
and purified as previously described (Miranda et al., 2012; Ray and Gage, 2006) with minor 
modifications. Enzymatically dissociated cells were cultured for 2 to 3 weeks, and then shaken 
overnight when the cells reached confluency to eliminate contaminating microglia.  Adhered confluent 
astrocytes were treated with cytosine arabinose (20 µM) for 48 hours to kill rapidly dividing cells and 
microglia.  Astrocytes were cultured in DMEM GlutaMAXTM DMEM + 10% FBS + N2 + antibiotic-
antimycotic (all from Life Technologies). 
Isolation and culture of adult primary microglia 
Adult microglia were isolated from brains of SOD1-G93A and WT littermates as previously 
described (Moussaud and Draheim, 2010) with minor modifications.  4-month old SOD1-G93A and 
WT littermate mice were deeply anesthetized and perfused transcardially with ice-cold Ringers 
solution (Fisher Scientific).  Brains that appeared to not be fully exsanguinated were discarded.  
Brains were fragmented with a scalpel and incubated with an enzymatic solution containing papain for 
60 minutes at 37°C, 5% CO2.  The papain solution was quenched with 20% FBS in HBSS and 
centrifuged for 4 minutes at 200g.  The pellet was resuspended in 2ml of 0.5 mg/ml DNase I 
(Worthington Biochemical) in HBSS and incubated for 5min at room temperature.  The brain tissue 
was gently disrupted with fire-polished Pasteur pipettes and then filtered through a 70 micron cell 
strainer (Fisher Scientific) and centrifuged at 200g for 4 minutes.  The resulting pellet was then 
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resuspended in 20ml of 20% isotonic Percoll (GE healthcare) in HBSS.  20mL of pure HBSS was 
carefully laid on top the percoll layer and centrifugation was performed at 200g for 20 min with slow 
acceleration and no brake.  The interphase layer containing myelin and cell debris was discarded, 
and the pellet containing the mixed glial cell population was washed once with HBSS and suspended 
in Dulbecco’s modified Eagle’s/F12 medium with GlutaMAXTM (DMEM/F12) supplemented with 10% 
heat inactivated FBS, antibiotic-antimycotic (all from Life Technologies) and 5 ng/ml of carrier-free 
murine recombinant granulocyte and macrophage colony stimulating factor (GM-CSF) (R&D 
systems). The cell suspension from four mouse brains were plated on a 15cm2 plate (Corning) 
coated with poly-l-lysine (Sigma) and maintained in culture at 37°C in a 95% air/ 5% CO2. The 
medium was replaced every 3 days until the cells reached confluency (after approximately 2 weeks).  
After the glial layer becomes confluent, microglia form a non-adherant, floating cell layer that can be 
collected, replated, and cultured for an extended period of time.  After collecting the floating layer, 
microglia were incubated for 3 days without GM-CSF before re-plating for co-culture with MNs.  
Collected microglia were characterized by immunocytochemistry and flow cytometry (antibodies listed 
in Supplementary Table 1).  Direct isolation of microglia for western blot analysis was performed as 
previously described (Cardona et al., 2006; Henry et al., 2009). 
Isolation and culture of primary neonatal microglia 
 Microglia cultures were prepared from 3-day old SOD1-G93A and wild-type littermate pups as 
previously described with some minor modifications (Xiao et al., 2007).  After removing meninges, 
cortices were dissociated and digested with 0.1% trypsin at 37°C for 15 minutes.  Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10% FBS (Life Technologies) and DNase I 
(Worthington Biochemical) was added to the tissue homogenate.  After centrifugation at 1200 RPM 
for 4 minutes, the cellular pellet was resuspended in DMEM with 10% FBS and plated 75cm2 flasks.  
Medium was replaced 24 hours after plating.  After 1 week incubation, the flasks were shaken 
	  
	  
46	  
	  
overnight at 250 RPM at 37°C.  After collection, the microglia were plated for co-culture with motor 
neurons at a density of 6,000 cells per 96-well as described in the “Microglia/MN co-culture” 
experimental procedures section. 
MN differentiation 
Mouse embryonic stem cells expressing GFP driven by the Hb9 promoter (HBG3 cells, kind 
gift from Tom Jessell) were cultured on primary mouse embryonic fibroblasts (Millipore) and 
differentiated to MNs with the addition of 2 µM retinoic acid (Sigma) and 2 µM purmorphamine 
(Calbiochem). After 5 days of differentiation, the embryoid bodies were dissociated and sorted for 
GFP on a FACSVantage/DiVa sorter (Becton Dickinson). 
ELISAs 
TNFα Quantikine ELISA kit (R&D Systems) was used according to manufacturer instructions to 
quantify the TNFα concentration in co-culture medium.  Nitric oxide levels in the co-culture medium 
were determined using the Total Nitric Oxide and Nitrate/Nitrite Parameter Kit (R&D Systems) 
according to manufacturer instructions. Co-culture medium was collected, centrifuged for 2 minutes at 
200g, and 50uL of medium was added to each well for analysis.  Phospho-p65 and Total p65 ELISA 
kits were used according to manufacturer instructions to quantify NF-κB activation in cell lysates (Cell 
Signaling).  All conditions were tested in triplicate.    
Virus production 
Transgenic SOD1 expression in microglia was knocked down by lentiviral transduction 
expressing short interfering RNA sequences previously described (Haidet-Phillips et al., 2011; Miller 
et al., 2006).  Lentivirus SOD1-shRNA and scramble-shRNA were produced by transient transfection 
into HEK293 cells using calcium phosphate, followed by supernatant viral purification by 
ultracentrifugation.  Adenoviral vectors (Ad-RFP, Ad-cre, and Ad-IκBα-SR) were purchase from 
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Vector Biolabs.  Microglia were infected with an MOI of 25 overnight, then washed with HBSS and 
incubated 3 days before co-culture with motor neurons.   
AAV9-IκBα-SR injections  
Adult tail vein injections were performed on 60 day old SOD1-G93A mice as previously 
described (Foust et al., 2008; 2010) with a 100 µl viral solution containing a mixture of PBS and 4 × 
1012 DNase-resistant particles of scAAV9-CB- IκBα-SR (Virapur).  
Flow cytometry of microglia cultures  
Flow cytometric analysis of microglial cell surface markers was performed by first blocking Fc 
receptors with anti-CD16/CD32 antibody (eBiosciences, CA). Next, cells were incubated with anti-
CD11b APC, anti-CD45 FITC (eBiosciences).  Expression of these surface receptors was determined 
by flow cytometry using a Becton-Dickinson LSR II Cytometer. Ten thousand events were collected 
and microglia incubated with isotype control were used as a negative control.  Flow data were 
analyzed using FlowJo software (Tree Star, San Carlos, CA). 
Luciferase reporter assays 
Primary microglia were plated at a density of 2 × 104 cells and transduced with 10 multiplicity 
of infection (MOI) of the inducible NFκB-responsive firefly luciferase reporter and 1 MOI of the cignal™ 
lenti renilla control using SureENTRY transduction reagent according to manufacturer manual 
(SABioscience).  Adenoviral vectors encoding IκBα-SR and cre recombinase (Vector Biolabs) we 
used at an MOI of 25 to inhibit NF-κB.  The cells were washed with PBS 24 hours post-infection.  
Firefly and renilla luciferase activities were determined using the Dual-Glo Luciferase Assay System 
(Promega) 72 hours after transduction. The amount of firefly luciferase activity of the transduced cells 
was normalized to renilla luciferase activity.  
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